SLC22A5 Antibody

What is SLC22A5 and why is it important in research?

SLC22A5 (Solute Carrier Family 22 Member 5) is a high-affinity sodium-dependent carnitine cotransporter, also known as OCTN2 or organic cation/carnitine transporter 2. This protein is critically important in research because it is strongly expressed in kidney, skeletal muscle, heart and placenta, with particularly high expression in intestinal cell types affected by Crohn disease, including epithelial cells. SLC22A5 is also expressed in CD68 macrophage and CD43 T-cells but not in CD20 B-cells . The study of SLC22A5 has significant implications for understanding carnitine transport mechanisms, autoimmune conditions like rheumatoid arthritis, and metabolic disorders.

What is the molecular weight of SLC22A5 protein and how does this impact Western blot analysis?

The molecular weight of SLC22A5 is approximately 65 KD, with a calculated weight of 63 kD . When performing Western blot analysis, researchers should optimize separation conditions for proteins in this molecular weight range. Protein migration patterns may vary depending on post-translational modifications, which can affect the apparent molecular weight on SDS-PAGE gels. For optimal detection, use 8-10% polyacrylamide gels with appropriate molecular weight markers spanning 50-75 kD. Variations in observed molecular weight might indicate potential protein modifications or isoforms that could be biologically significant in your experimental system.

Which tissues show high expression of SLC22A5 and how should sample preparation be adjusted accordingly?

SLC22A5 is strongly expressed in kidney, skeletal muscle, heart, and placenta tissues . For these high-expression tissues, sample preparation methods should be optimized with the following approaches:

• For kidney samples: Use specialized lysis buffers containing protease inhibitors to preserve protein integrity while efficiently extracting membrane proteins.

• For skeletal muscle and heart: Implement mechanical homogenization followed by specialized extraction buffers containing detergents like NP-40 or Triton X-100 to solubilize membrane proteins.

• For placental tissue: Consider gradient centrifugation techniques to separate cellular components.

Sample dilutions should be carefully titrated for high-expression tissues to prevent oversaturation of signals in downstream applications. Preliminary experiments comparing extraction efficiencies across different buffer compositions are recommended for optimal results.

What are the most common applications for SLC22A5 antibodies in research?

• Immunohistochemistry (IHC) for paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples, particularly useful for examining expression patterns in kidney, heart, and intestinal tissues.

• Immunofluorescence (IF) and immunocytochemistry (ICC) for subcellular localization studies.

• ELISA for quantitative measurement of SLC22A5 levels in research samples.

When transitioning between applications, optimization of antibody concentration is essential, as dilution requirements vary significantly between Western blotting (typically 1:500-1:2000) and immunostaining techniques (often requiring higher concentrations).

How can I optimize antibody validation for SLC22A5 to ensure specificity in my experimental system?

For rigorous validation of SLC22A5 antibodies, implement a multi-step approach:

• Perform parallel Western blots using tissues with known differential expression (e.g., kidney vs. spleen) to confirm signal in high-expression tissues and minimal signal in low-expression tissues.

• Include knockout/knockdown controls where available, or use competing peptide assays with the immunizing peptide (e.g., amino acids 1-180 for antibodies like ABIN3022379) .

• Compare reactivity across multiple antibodies targeting different epitopes of SLC22A5 (e.g., N-terminal region AA 1-180 vs. C-terminal region).

• Confirm antibody specificity using orthogonal methods such as mass spectrometry or RNA expression data.

• Validate cross-reactivity in non-human samples if performing comparative studies across species, noting that some antibodies show reactivity to human, rat, and mouse SLC22A5 .

Document all validation steps meticulously to establish confidence in antibody specificity before proceeding with experimental studies.

What are the key considerations when designing experiments to study SLC22A5 polymorphisms and their functional consequences?

When investigating SLC22A5 polymorphisms, such as the 207C>G (rs2631367) variant studied in rheumatoid arthritis , implement the following experimental design considerations:

• Genotyping approach: Use validated TaqMan genotyping assays with appropriate controls, including known homozygous and heterozygous samples .

• Sample size calculation: Perform power analysis to determine adequate sample numbers for detecting genotype-phenotype associations.

• Population stratification: Account for ethnic background variations that might influence polymorphism frequencies.

• Functional assessment: Design transport assays to measure functional differences between variants, focusing on carnitine transport efficiency.

• Gene-environment interactions: Consider environmental factors that might modify the effect of polymorphisms.

• Clinical correlation: Establish clear phenotyping criteria when associating polymorphisms with disease manifestations (e.g., extra-articular manifestations in rheumatoid arthritis) .

How should contradictory results in SLC22A5 expression studies be analyzed and interpreted?

When encountering contradictory results in SLC22A5 expression studies, employ this systematic analytical approach:

• Methodological assessment: Compare antibody clones, epitopes (e.g., N-terminal AA 1-180 vs. C-terminal regions), and detection methods used across studies .

• Sample preparation variables: Evaluate differences in tissue processing, protein extraction protocols, and storage conditions.

• Species differences: Consider that expression patterns may legitimately differ between human, rat, and mouse samples, even when using antibodies with cross-reactivity to multiple species .

• Isoform specificity: Determine whether contradictory results might reflect detection of different SLC22A5 splice variants.

• Pathological context: Analyze whether disease states (e.g., Crohn's disease, rheumatoid arthritis) might alter expression patterns compared to healthy tissues .

• Quantification methods: Re-analyze data using standardized quantification approaches with appropriate housekeeping controls.

Contradictory findings should be reported transparently with detailed methodological documentation to advance understanding of context-dependent SLC22A5 expression patterns.

What experimental approaches can be used to study SLC22A5's role in drug transport and pharmacokinetics?

To investigate SLC22A5's function in drug transport and pharmacokinetics, implement these experimental approaches:

• Heterologous expression systems: Establish stable cell lines overexpressing SLC22A5 variants to measure transport of radiolabeled or fluorescently labeled substrates.

• Competitive inhibition assays: Determine substrate specificity by measuring carnitine transport in the presence of potential inhibitors or drug compounds.

• Site-directed mutagenesis: Create SLC22A5 mutants to identify critical residues for transport function and drug interactions.

• Patient-derived samples: Analyze SLC22A5 variants in relation to drug efficacy, such as methotrexate response in rheumatoid arthritis patients with different genotypes (GG, GC, CC) .

• In vivo pharmacokinetic studies: Design animal studies comparing drug disposition in wild-type versus SLC22A5-modified models.

• Bidirectional transport assays: Utilize polarized cell monolayers to assess directional drug transport mediated by SLC22A5.

This multifaceted approach can elucidate SLC22A5's contribution to drug disposition and potential role in drug-drug interactions or personalized medicine applications.

How can epitope mapping influence SLC22A5 antibody selection for specific research applications?

Epitope mapping is crucial for selecting the optimal SLC22A5 antibody for specific research questions. Different antibodies recognize distinct regions of the SLC22A5 protein:

• N-terminal targeted antibodies (e.g., AA 1-180) : These antibodies recognize epitopes within the first 180 amino acids of SLC22A5 and may be advantageous for:

  • Detecting full-length protein

  • Applications where the C-terminus might be obscured in protein complexes

  • Distinguishing between potential N-terminal splice variants

• C-terminal targeted antibodies: These recognize epitopes near the carboxyl terminus and are valuable for:

  • Detecting truncation mutants

  • Applications where the N-terminus might be post-translationally modified

  • Distinguishing between C-terminal variants

• Internal region-specific antibodies (e.g., AA 42-142): These target central domains and can be useful for:

  • Applications where terminal epitopes might be inaccessible

  • Detecting core functional domains independent of terminal modifications

When selecting between antibodies targeting different epitopes, consider potential protein processing events, membrane topology, and the conformational state of the protein in your experimental system.

What are the implications of SLC22A5 polymorphisms for treatment response in autoimmune conditions?

Research on SLC22A5 polymorphisms suggests potential implications for treatment response in autoimmune conditions, though current evidence shows nuanced relationships:

Based on studies of the 207C>G polymorphism (rs2631367) in rheumatoid arthritis patients, treatment efficacy shows subtle genotype-dependent patterns. Data indicates that among patients with different SLC22A5 genotypes treated with methotrexate (MTX), remission rates were:

• 48.5% in patients with GG genotype

• 49.3% in patients with GC genotype

• 46.3% in patients with CC genotype

These differences did not reach statistical significance, suggesting that while this specific polymorphism may influence disease susceptibility or manifestations, it may not be a strong predictor of treatment response .

When designing studies to further explore this relationship, researchers should:

• Incorporate larger sample sizes to detect potentially subtle effects

• Consider haplotype analysis rather than single polymorphism assessment

• Evaluate interaction effects between SLC22A5 variants and other pharmacogenetic markers

• Include detailed phenotyping of response patterns beyond binary responder/non-responder classifications

How should researchers control for tissue-specific expression patterns when using SLC22A5 antibodies?

When controlling for tissue-specific expression patterns of SLC22A5, implement these methodological safeguards:

• Reference tissue panel: Include positive control tissues with known high expression (kidney, heart, skeletal muscle, placenta) and negative control tissues with minimal expression in all experiments .

• Quantitative calibration: Develop standard curves using recombinant SLC22A5 protein to enable cross-tissue comparison of expression levels.

• Cell type-specific resolution: When working with heterogeneous tissues, complement whole-tissue Western blot with immunohistochemistry or single-cell approaches to identify specific expressing cell populations (e.g., epithelial cells in intestinal tissue, CD68 macrophages, CD43 T-cells) .

• Transcript validation: Perform parallel qRT-PCR analysis of SLC22A5 mRNA to corroborate protein-level findings.

• Subcellular localization assessment: Use fractionation approaches to distinguish membrane-localized from cytoplasmic protein pools, as functional SLC22A5 should primarily localize to plasma membranes.

This comprehensive approach enables accurate interpretation of SLC22A5 expression patterns while avoiding artifacts related to tissue composition or antibody cross-reactivity.

How can signal specificity issues be addressed when using SLC22A5 antibodies for Western blotting?

When encountering signal specificity issues with SLC22A5 antibodies in Western blotting, implement this systematic troubleshooting approach:

• Blocking optimization: Test different blocking agents (BSA vs. non-fat dry milk) at various concentrations (3-5%) to reduce non-specific binding.

• Antibody titration: Perform dilution series of primary antibody (1:500 to 1:5000) to identify the optimal concentration that maximizes specific signal while minimizing background.

• Washing stringency: Increase TBST (Tris-buffered saline with Tween) concentration from 0.05% to 0.1% Tween-20 and extend washing duration to reduce non-specific binding.

• Sample preparation refinement: Implement additional centrifugation steps post-lysis to remove insoluble material that might cause non-specific binding.

• Peptide competition: Pre-incubate the antibody with excess immunizing peptide (e.g., amino acids 1-180 for ABIN3022379) to confirm signal specificity.

• Cross-validation: Compare results across multiple antibodies targeting different epitopes of SLC22A5 to distinguish true signal from artifacts.

This systematic approach can significantly improve signal specificity and confidence in experimental findings.

What considerations are important when designing experiments to study SLC22A5's role in carnitine transport mechanisms?

When investigating SLC22A5's role in carnitine transport mechanisms, implement these experimental design considerations:

• Functional assay selection:

  • For kinetic analyses: Use radiolabeled carnitine uptake assays with time-course measurements

  • For inhibition studies: Implement competitive uptake experiments with varying concentrations of inhibitors

  • For directional transport: Employ transwell systems with polarized cell monolayers

• Expression system optimization:

  • Consider both transient and stable expression systems for functional studies

  • Validate expression levels by Western blot using validated antibodies

  • Use inducible expression systems to control protein levels

• Mutagenesis approach:

  • Design mutations targeting predicted transmembrane domains

  • Focus on conserved residues identified through sequence alignments

  • Include positive controls (known functional mutations) and negative controls (synonymous mutations)

• Physiological relevance:

  • Maintain physiological temperature (37°C) during transport assays

  • Include pH and ion dependency analyses to mimic in vivo conditions

  • Consider co-expression of interacting proteins that might modulate transport

• Data analysis rigor:

  • Fit kinetic data to appropriate models (Michaelis-Menten, Hill equation)

  • Calculate transport parameters (Km, Vmax) with appropriate statistical analysis

  • Normalize data to account for variations in expression levels

This comprehensive approach enables robust characterization of SLC22A5's carnitine transport mechanisms under physiologically relevant conditions.

How can CRISPR-Cas9 gene editing be utilized to study SLC22A5 function and regulation?

CRISPR-Cas9 technology offers powerful approaches for investigating SLC22A5 function and regulation:

• Knockout models: Generate SLC22A5-null cellular models to:

  • Establish antibody specificity by eliminating target protein

  • Create negative control cell lines for transport assays

  • Identify compensatory mechanisms that activate upon SLC22A5 loss

• Knock-in strategies:

  • Introduce polymorphic variants (e.g., 207C>G) to study functional consequences

  • Create fluorescent protein fusions for live-cell imaging of trafficking and localization

  • Engineer epitope tags for antibody-independent detection

• Promoter editing:

  • Modify the heat shock element in the 5′-UTR of SLC22A5 to study transcriptional regulation

  • Engineer inducible promoter systems to control expression timing and magnitude

  • Create reporter constructs to monitor promoter activity in different cellular contexts

• Multiplexed approaches:

  • Simultaneously target SLC22A5 and interacting partners to study functional relationships

  • Create cellular models with multiple polymorphisms to study combinatorial effects

  • Generate tissue-specific knockout models using appropriate promoters

When implementing CRISPR-Cas9 approaches, thorough validation of edited clones using sequencing, expression analysis with validated antibodies , and functional characterization is essential.

What are the emerging techniques for studying SLC22A5 protein-protein interactions and their functional significance?

Cutting-edge approaches for investigating SLC22A5 protein-protein interactions include:

• Proximity labeling approaches:

  • BioID or TurboID fusion proteins to identify proximal proteins in living cells

  • APEX2-based labeling for temporal resolution of interaction dynamics

  • Split-BioID for studying conditional interactions

• Cross-linking mass spectrometry (XL-MS):

  • Identify direct binding partners through chemical cross-linking followed by proteomics

  • Map interaction interfaces at amino acid resolution

  • Detect transient interactions that might be lost in traditional co-immunoprecipitation

• Förster Resonance Energy Transfer (FRET):

  • Live-cell imaging of protein interactions with spatial and temporal resolution

  • Measure interaction distances using fluorescent protein pairs

  • Study the impact of mutations or drug treatments on interaction dynamics

• Single-molecule approaches:

  • Direct visualization of interaction kinetics using fluorescently labeled proteins

  • Measure binding/unbinding events in real-time

  • Determine stoichiometry of protein complexes

• Computational approaches:

  • Molecular dynamics simulations of SLC22A5 interactions

  • Protein-protein docking based on structural data

  • Identification of potential interacting partners through co-expression network analysis

These techniques provide complementary insights into SLC22A5 interaction networks that regulate its localization, activity, and physiological functions.